In a study evaluating patient-derived models of FGFR2-fusion-positive cholangiocarcinoma, inhibition of EGFR potentiated responses to FGFR inhibitors, durably suppressing MEK/ERK and mTOR signaling, increasing apoptosis, and causing marked tumor regressions in vivo. The gene discussed is FGFR2; the disease is cholangiocarcinoma.